BDTX vs. SRPT

Last updated Apr 2, 2026

Compare and contrast key facts about Black Diamond Therapeutics, Inc. (BDTX) and Sarepta Therapeutics, Inc. (SRPT).

Performance

BDTX vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Black Diamond Therapeutics, Inc. (BDTX) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

BDTX vs. SRPT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
BDTX Black Diamond Therapeutics, Inc.	-4.12%	13.55%	-23.84%	56.11%	-66.23%	-83.37%	-18.82%
SRPT Sarepta Therapeutics, Inc.	2.83%	-82.30%	26.09%	-25.58%	43.90%	-47.18%	44.70%

Fundamentals

EPS BDTX : $0.38 SRPT : -$8.11
PS Ratio BDTX : 1.89 SRPT : 1.05
Total Revenue (TTM) BDTX : $70.00M SRPT : $2.20B
Gross Profit (TTM) BDTX : $69.91M SRPT : -$1.05B
EBITDA (TTM) BDTX : $17.54M SRPT : -$778.95M

Returns By Period

In the year-to-date period, BDTX achieves a -4.12% return, which is significantly lower than SRPT's 2.83% return.

BDTX

• 1D: 9.39%
• 1M: -4.12%
• YTD: -4.12%
• 6M: -37.37%
• 1Y: 56.38%
• 3Y*: 7.23%
• 5Y*: -38.02%
• 10Y*: —

SRPT

• 1D: 1.70%
• 1M: 35.60%
• YTD: 2.83%
• 6M: 14.54%
• 1Y: -64.25%
• 3Y*: -45.65%
• 5Y*: -21.91%
• 10Y*: 1.03%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BDTX vs. SRPT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BDTX

BDTX Risk / Return Rank: 62
BDTX Sharpe Ratio Rank: 67
BDTX Sortino Ratio Rank: 65
BDTX Omega Ratio Rank: 62
BDTX Calmar Ratio Rank: 60
BDTX Martin Ratio Rank: 57

SRPT

SRPT Risk / Return Rank: 18
SRPT Sharpe Ratio Rank: 15
SRPT Sortino Ratio Rank: 20
SRPT Omega Ratio Rank: 18
SRPT Calmar Ratio Rank: 12
SRPT Martin Ratio Rank: 23

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BDTX vs. SRPT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Black Diamond Therapeutics, Inc. (BDTX) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BDTX	SRPT	Difference
Sharpe ratio Return per unit of total volatility	0.75	-0.59	+1.34
Sortino ratio Return per unit of downside risk	1.40	-0.42	+1.82
Omega ratio Gain probability vs. loss probability	1.18	0.93	+0.25
Calmar ratio Return relative to maximum drawdown	0.86	-0.80	+1.67
Martin ratio Return relative to average drawdown	1.68	-1.03	+2.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BDTX vs. SRPT - Sharpe Ratio Comparison

The current BDTX Sharpe Ratio is 0.75, which is higher than the SRPT Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of BDTX and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BDTX	SRPT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.75	-0.59	+1.34
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	-0.32	+0.03
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	-0.02	-0.28

Correlation

The correlation between BDTX and SRPT is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BDTX vs. SRPT - Dividend Comparison

Neither BDTX nor SRPT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BDTX vs. SRPT - Drawdown Comparison

The maximum BDTX drawdown since its inception was -97.21%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for BDTX and SRPT.

Drawdown Indicators

	BDTX	SRPT	Difference
Max Drawdown Largest peak-to-trough decline	-97.21%	-98.17%	+0.96%
Max Drawdown (1Y) Largest decline over 1 year	-58.32%	-81.26%	+22.94%
Max Drawdown (5Y) Largest decline over 5 years	-95.56%	-92.72%	-2.84%
Max Drawdown (10Y) Largest decline over 10 years	—	-93.33%	—
Current Drawdown Current decline from peak	-94.80%	-87.62%	-7.18%
Average Drawdown Average peak-to-trough decline	-78.16%	-68.02%	-10.14%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.87%	63.52%	-33.65%

Volatility

BDTX vs. SRPT - Volatility Comparison

The current volatility for Black Diamond Therapeutics, Inc. (BDTX) is 25.49%, while Sarepta Therapeutics, Inc. (SRPT) has a volatility of 34.93%. This indicates that BDTX experiences smaller price fluctuations and is considered to be less risky than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BDTX	SRPT	Difference
Volatility (1M) Calculated over the trailing 1-month period	25.49%	34.93%	-9.44%
Volatility (6M) Calculated over the trailing 6-month period	53.73%	70.71%	-16.98%
Volatility (1Y) Calculated over the trailing 1-year period	75.54%	109.93%	-34.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	132.25%	69.76%	+62.49%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	124.05%	75.46%	+48.59%

Financials